Dr Reddy's Laboratories Shares Rise After Acquiring Haleon’s Nicotine Replacement Therapy

Dr Reddy's Laboratories Shares Rise After Acquiring Haleon’s Nicotine Replacement Therapy

A also set a target of Rs 6,500 for its shares. Interestingly, at the halfway mark of the intraday trading session, the company shares zoomed by over 2 per cent, taking them past the previously mentioned target of Rs 6,500.

G R MukeshUpdated: Wednesday, July 03, 2024, 01:19 PM IST
article-image

Hyderabad-based Dr Reddy Laboratories, one of the more-noticed names in the pharma business, has been in the headlines for the past few days now. In a recent development, the company shares jumped over 2 per cent in intraday trade on Wednesday, July 3.

Dr Reddy's Acquires NRT

This development came to pass after the pharma company's acquisition plans for British pharma company Haleon's Nicotine Replacement Therapy were made public.

In addition, this rise in shares comes just a few days after stock broking company Prabhudas Lilladher issued a Buy call for the company shares.

In addition, this rise in shares comes just a few days after stock broking company Prabhudas Lilladher issued a Buy call for the company shares. |

The company is reported to have spent Rs 5,301 crore on the deal. This move is expected to help the company's over-the-counter business.

In addition, this rise in shares comes just a few days after stockbroking company Prabhudas Lilladher issued a 'Buy' call for the company's shares.

The brokerage company also set a target of Rs 6,500 for its shares. Interestingly, at the halfway mark of the intraday trading session, the company shares zoomed by over 2 per cent, taking them past the previously mentioned target of Rs 6,500.

When it comes to the company's Q4 performance, the company's overall revenue came up to Rs 7,083 crore in the final quarter of FY24.

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates.

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates. | Representational Image/Pixabay

Shares Rise By Over 1%

This marked a 12.5 per cent jump in its previous cycle, when it was at Rs 6,297 crore. In addition, it had a consolidated net profit of Rs 1,307 crore. However, according to reports, it was still below estimates.

After a great start to the day, Dr Reddy's Laboritaries shares, which surged by over 2 per cent, tapered away and lost their momentum slightly as the surge declined marginally. At 13:11, the company shares increased by 1.37 per cent or Rs 87.10, taking the cumulative value to Rs 6,457.35 per share.

Meanwhile, some of the other pharma stocks are trading in red. Divi Laboratories and Cipla declined by under 0.50 per cent, while Sun Pharma is trading at an increase of 0.056 per cent.  

RECENT STORIES

FlowerAura Redefines Flower Gifting: Celebrating Life’s Small Moments

FlowerAura Redefines Flower Gifting: Celebrating Life’s Small Moments

Innovative Application Logging: Reducing Downtime With Automation

Innovative Application Logging: Reducing Downtime With Automation

Harnessing Machine Learning For Accurate Credit Assessments: Sree Sandhya Kona’s Innovative...

Harnessing Machine Learning For Accurate Credit Assessments: Sree Sandhya Kona’s Innovative...

Hinduja Tech To Acquire Tecosim Group for 21 Million Euros

Hinduja Tech To Acquire Tecosim Group for 21 Million Euros

Feature-Packed: Samsung Galaxy M35 5G Launched in India

Feature-Packed: Samsung Galaxy M35 5G Launched in India